New Horizon Health
Researches and develops technology for early-stage cancer screening.
Launch date
Employees
Market cap
€733m
Enterprise valuation
€733m (Public information from Sep 2024)
Share price
HKD14.14 6606.HK
Hangzhou Zhejiang (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 58.3m | 70.6m | 213m | 765m | 2.0b | 2.9b | 3.9b |
| % growth | - | 21 % | 202 % | 260 % | 163 % | 44 % | 33 % |
| EBITDA | (89.2m) | (751m) | (3.0b) | (27.9m) | 36.0m | 501m | 1.2b |
| % EBITDA margin | (153 %) | (1064 %) | (1431 %) | (4 %) | 2 % | 17 % | 32 % |
| Profit | (106m) | (789m) | (3.1b) | (79.2m) | 218m | 218m | 360m |
| % profit margin | (183 %) | (1118 %) | (1450 %) | (10 %) | 11 % | 8 % | 9 % |
| EV / revenue | - | - | 28.8x | 7.6x | 2.9x | 2.0x | 1.5x |
| EV / EBITDA | - | - | -2.0x | -208.2x | 162.8x | 11.7x | 4.8x |
| R&D budget | 26.4m | 25.3m | 58.9m | 94.6m | - | - | - |
| R&D % of revenue | 45 % | 36 % | 28 % | 12 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Series A | ||
$20.0m | Series B | ||
$66.0m | Series C | ||
* | $20.0m | Series D | |
$30.0m | Series E | ||
| N/A | $263m | IPO | |
| Total Funding | €124m | ||
Recent News about New Horizon Health
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
ACQUISITION by Onconetix Dec 2023